GI
VTGN icon

Gradient Investments’s VistaGen Therapeutics VTGN Stock Holding History

Gradient Investments’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1
Closed – – 1670
2022
Q3 		$0 Hold
1
– – ﹤0.01% 1551
2022
Q2 		$0 Hold
1
– – ﹤0.01% 1389
2022
Q1 		$0 Hold
1
– – ﹤0.01% 1353
2021
Q4 		$0 Hold
1
– – ﹤0.01% 1336
2021
Q3 		$0 Hold
1
– – ﹤0.01% 1261
2021
Q2 		$0 Hold
1
– – ﹤0.01% 1266
2021
Q1 		$0 Hold
1
– – ﹤0.01% 1300
2020
Q4 		$0 Hold
1
– – ﹤0.01% 1183
2020
Q3 		$0 Hold
1
– – ﹤0.01% 1229
2020
Q2 		$0 Sell
1
-2
-67% -$27 ﹤0.01% 1211
2020
Q1 		$0 Buy
+3
New +$55 ﹤0.01% 1254

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Gradient Investments's VTGN Position: Q4 2022 in Review

Gradient Investments sold out of VistaGen Therapeutics (VTGN) in Q4 2022, closing a stake of 1 share.

Gradient Investments first reported a position in VTGN in Q1 2020 and held it in 11 quarters. The position peaked at $0 in Q3 2022. 85 funds tracked by Wall St. Rank hold VTGN as of Q4 2022.

  • Gradient Investments reported no remaining VistaGen Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Gradient Investments sold 1 VistaGen Therapeutics share in Q4 2022.
  • Gradient Investments first reported a position in VistaGen Therapeutics in Q1 2020 and held it in 11 quarters.
  • Gradient Investments's VistaGen Therapeutics position peaked at $0 in Q3 2022.
  • 85 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2022.

Based on Gradient Investments's 13F filing for Q4 2022, filed 10 Jan 2023.